PLUR

Pluristem Therapeutics Inc. (PSTI) - 10-K Summary

Business Context and Reporting Period

Company: Pluristem Therapeutics Inc.
Reporting Period: Fiscal year ended June 30, 2009
Business Model: Development-stage biotechnology company focused on commercializing allogeneic (non-personalized) cell therapy products derived from human placenta. The company utilizes a proprietary 3D bioreactor system (PluriX) to expand placental adherent stromal cells (PLX cells).
Key Milestone: In July 2009, the company enrolled the first patient in a Phase I clinical trial for its lead product, PLX-PAD, intended to treat critical limb ischemia (CLI). U.S. trials began in September 2009.

Key Financial Metrics

Note: Financial statements are presented in thousands of U.S. dollars. The company has no debt listed on the balance sheet as of June 30, 2009, other than accrued liabilities and long-term obligations related to severance and leases.

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by approximately 37% from $10.5 million in 2008 to $6.6 million in 2009. This improvement was driven by a significant reduction in stock-based compensation expenses due to a lower stock price and increased grant participation from the Israeli Office of the Chief Scientist (OCS).
• Expense Reductions:
  • R&D Expenses: Decreased 28% to $3.1 million, primarily due to lower stock-based compensation ($1.0 million reduction) and higher OCS grant offsets.
  • G&A Expenses: Decreased 43% to $3.4 million, largely due to a $1.9 million reduction in stock-based compensation and reduced investor relations costs.
• Liquidity Improvement: Cash and cash equivalents increased significantly from $323,000 to $2.3 million, fueled by $5.4 million in financing activities (equity issuances) and $1.4 million in OCS grants received during the year.

Guidance, Outlook, and Risks

Outlook and Guidance:

• The company does not expect to generate product revenue in the next 12 months.
• Management estimates cash expenses for the next 12 months to be approximately $6.0 million ($4.0 million for R&D and $2.0 million for G&A).
• Based on current cash and an approved $2.3 million OCS grant, management believes funds are sufficient to operate until at least March 2010.
• Future funding will likely require additional equity issuances or non-dilutive grants.

Risks and Contingencies:

• Going Concern: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to the lack of revenue and history of losses.
• Regulatory Approval: Commercialization depends entirely on successful clinical trials and regulatory approvals (FDA/EMA), which are uncertain and costly.
• Financing: The company is dependent on raising additional capital. Failure to do so could force a cessation of operations.
• Legal/Contractual: A potential conflict exists regarding a May 2007 financing agreement that restricted share sales below a certain price floor. The company proceeded with lower-priced offerings, issuing warrants to investors as a potential release from liability.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $2.3 million OCS grant and current cash balance to sustain operations through March 2010 as projected.
• Clinical Trial Progress: Monitor enrollment rates and safety data from the Phase I PLX-PAD trials in the U.S. and Germany.
• Dilution Risk: Assess the impact of future equity offerings required to fund operations beyond March 2010.
• Legal Exposure: Review the status of the potential litigation regarding the May 2007 financing agreement price floor provision.
• Grant Dependency: Evaluate the company's reliance on the Israeli Office of the Chief Scientist for R&D funding and the conditions attached to these grants.